Refractory high-risk mucous membrane pemphigoid treated with Telitacicept

Clicks: 2
ID: 315058
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #241 of 313 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We report a patient with high-risk, treatment-refractory mucous membrane pemphigoid who achieved sustained clinical remission following B-lymphocyte stimulator (BLyS)/a proliferation-inducing ligand (APRIL) inhibition with telitacicept, supported by longitudinal disease activity assessment and immunological monitoring. To our knowledge, this represents the first reported use of telitacicept in mucous membrane pemphigoid in the English-language literature, suggesting a potential therapeutic role for BLyS/APRIL pathway inhibition in refractory high-risk MMP cases.
Reference Key
openalex_W7162532354 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xun Feng, Mintong Wei, Yì Wáng, Yue Xiao, Jishu Li, Min Zou, Li X, Hua Qian, Wei Li
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag217
URL
https://doi.org/10.1093/bjd/ljag217
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.